<div id="readability-page-1"><p>Commerzbank Aktiengesellschaft FI purchased a new position in  Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 25,417 shares of the biopharmaceutical company's stock, valued at approximately $982,000.</p><div><p><span></span><span>Get <strong>Royalty Pharma</strong> alerts:</span></p></div><ul><li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li></ul><p>Several other hedge funds and other institutional investors have also made changes to their positions in RPRX. Capital International Investors boosted its position in shares of  Royalty Pharma by 24.4% in the 3rd quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company's stock worth $960,064,000 after purchasing an additional 5,332,074 shares during the last quarter.  Dorsey Asset Management LLC bought a new position in shares of  Royalty Pharma in the 3rd quarter worth $82,924,000.  Qube Research &amp; Technologies Ltd boosted its position in shares of  Royalty Pharma by 737.3% in the 3rd quarter. Qube Research &amp; Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company's stock worth $87,557,000 after purchasing an additional 2,185,366 shares during the last quarter.  Millennium Management LLC boosted its position in shares of  Royalty Pharma by 379.2% in the 3rd quarter. Millennium Management LLC now owns 2,235,133 shares of the biopharmaceutical company's stock worth $78,855,000 after purchasing an additional 1,768,702 shares during the last quarter.  Finally, Clark Capital Management Group Inc. bought a new position in shares of  Royalty Pharma in the 3rd quarter worth $61,805,000. 54.35% of the stock is currently owned by institutional investors. </p><h2>Analyst Ratings Changes</h2><p>Several research firms have recently issued reports on RPRX. The Goldman Sachs Group  restated a &#34;buy&#34; rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Weiss Ratings upgraded Royalty Pharma from a &#34;buy (b-)&#34; rating to a &#34;buy (b)&#34; rating in a report on Friday, May 1st. Citigroup lifted their target price on Royalty Pharma from $50.00 to $66.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, May 7th. Morgan Stanley lifted their target price on Royalty Pharma from $61.00 to $63.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, April 10th. Finally, UBS Group lifted their target price on Royalty Pharma from $51.00 to $57.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, April 21st. Seven investment analysts have rated the stock with a Buy rating,  Based on data from MarketBeat.com, the stock  has a consensus rating of &#34;Buy&#34; and a consensus target price of $53.71.</p><ul><li>1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data</li></ul><p><b>Get Our Latest Research Report on Royalty Pharma</b></p><h2>Insider Activity</h2><p>In other news, Director Gregory Norden sold 3,045 shares of the business's stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the sale, the director directly owned 191,803 shares in the company, valued at $10,165,559. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the business's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 155,893 shares of company stock worth $7,512,360 over the last three months. Corporate insiders own  18.84% of the company's stock. </p><h2>Royalty Pharma Stock Performance</h2><ul><li>4 Healthcare Stocks With Massive Gains—and More to Come</li></ul><p>RPRX stock opened at $52.85 on Friday. The business's 50-day moving average price is $48.31 and its two-hundred day moving average price is $43.35. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The firm has a market cap of $30.43 billion, a PE ratio of 35.95, a P/E/G ratio of 1.45 and a beta of 0.40. Royalty Pharma PLC has a 1-year low of $32.15 and a 1-year high of $53.47. </p><p>Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. The firm had revenue of $631.00 million for the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. As a group, research analysts forecast that  Royalty Pharma PLC will post 5.05 earnings per share for the current year. </p><h2>Royalty Pharma Announces Dividend</h2><p>The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma's payout ratio is 63.95%. </p><h2>Royalty Pharma Company Profile</h2> (Free Report)<p>Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.  </p><p>The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Royalty Pharma</li><li>3 Stocks to Own If Gas Prices Keep Rising</li><li>3 Crucial Aerospace Component Makers That Analysts Love</li><li>Alphabet's Googlebook Brings Gemini AI to PC Hardware</li><li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Royalty Pharma Right Now?</h2><p>Before you consider Royalty Pharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.</p><p>While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RPRX

<p>Commerzbank Aktiengesellschaft FI invested approximately $982,000 in Royalty Pharma PLC by purchasing 25,417 shares during the 4th quarter. Other institutional investors have also increased their stakes in the company. Analysts maintain a consensus 'Buy' rating for Royalty Pharma, with target prices ranging from $51.00 to $66.00. The stock opened at $52.85, with a market cap of $30.43 billion and a PE ratio of 35.95.</p>

Market Beat

Royalty Pharma PLC - CL

iShares US Pharma

Commerzbank AG

Goldman Sachs

Citigroup

Morgan Stanley

UBS Group AG

Zenas Biopharma

GS Hldg R

CITIGROUP INC 6.250 NON CUM SER II PFD WI

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX